Sponsor Data Must Support Need for Excess Drugs in Injectable Products

Drug Industry Daily
A A
The FDA is asking sponsors of BLAs, NDAs, and ANDAs to justify the amount of excess medication for injectable drug products they plan to pack in vials and ampules.

To View This Article:

Login

Subscribe To Drug Industry Daily